Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States

In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB...

Full description

Bibliographic Details

Published in:	Clinical infectious diseases Vol. 71; no. 4; p. 1010
Main Authors:	Mase, Sundari, Chorba, Terence, Parks, Samuel, Belanger, Ann, Dworkin, Felicia, Seaworth, Barbara, Warkentin, Jon, Barry, Pennan, Shah, Neha
Format:	Journal Article
Language:	English
Published:	United States 14.08.2020
Subjects:	Antitubercular Agents - adverse effects Diarylquinolines - adverse effects Humans Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy United States - epidemiology United States treatment adverse event multidrug-resistant tuberculosis bedaquiline outcome
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!